Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alimera submits NDA to the FDA for Iluvien in diabetic macular edema

July 6, 2010

No Comments

Otsuka and MethylGene extend collaboration for kinase inhibitors in ocular diseases

July 5, 2010

No Comments

InNexus develops protein for potential use in AMD

July 5, 2010

No Comments

Alimera submits Iluvien NDA to FDA for diabetic macular edema

July 1, 2010

No Comments

Quark Pharmaceuticals reports results for QPI-1007 in glaucoma model

June 30, 2010

No Comments

Pilot trial finds XOMA-052 beneficial in uveitis of Behcet's disease

June 29, 2010

No Comments

QLT reports on Visudyne-Lucentis combination in wet AMD

June 25, 2010

No Comments

FDA approves Lucentis for macular edema following retinal vein occlusion

June 25, 2010

No Comments

Inotek begins phase II trial of INO-8875 eye drops in glaucoma

June 21, 2010

No Comments

Catena demonstrates visual benefits in Leber's hereditary optic neuropathy

June 18, 2010

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Alimera submits NDA to the FDA for Iluvien in diabetic macular edema

Otsuka and MethylGene extend collaboration for kinase inhibitors in ocular diseases

InNexus develops protein for potential use in AMD

Alimera submits Iluvien NDA to FDA for diabetic macular edema

Quark Pharmaceuticals reports results for QPI-1007 in glaucoma model

Pilot trial finds XOMA-052 beneficial in uveitis of Behcet's disease

QLT reports on Visudyne-Lucentis combination in wet AMD

FDA approves Lucentis for macular edema following retinal vein occlusion

Inotek begins phase II trial of INO-8875 eye drops in glaucoma

Catena demonstrates visual benefits in Leber's hereditary optic neuropathy

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Ocular RSS

Ocular
RSS